Chinese
Japan
English
ProBio and AffyXell Therapeutics enter into a CDMO supply agreement for the development and production of genetically modified mesenchymal stem cells for therapeutics
ProBio intends to participate in AffyXell Therapeutics's next round of fundraising, which includes business development collaboration and licensing
May 16, 2022–ProBio, a worldwide leader in biopharmaceutical contract development and manufacturing organization (CDMO), today announced the continued partnership with AffyXell Therapeutics, a joint venture of United Kingdom-based Avacta Group and South Korea-based pharmaceutical company, Daewoong Pharmaceutical. This collaboration signifies ProBio's ongoing commitment to the advancement of novel gene therapies using mesenchymal stem cells for the treatment of autoimmune and inflammatory diseases.
ProBio has signed its second CDMO supply agreement with AffyXell Therapeutics for its second pipeline. This framework agreement will support the development and production of viral vectors required for cell therapy products using genetically modified mesenchymal stem cells developed by AffyXell Therapeutics. Today’s announcement follows an earlier strategic partnership agreement signed in December 2021 for AffyXell Therapeutics's first pipeline.
Jongsang Ryu, Chief Executive Officer of AffyXell Therapeutics, said: “This agreement will be an opportunity to accelerate the development of novel therapies for rare disease, providing meaningful options for patients.”
Brian Min, Ph.D., Chief Executive Officer of ProBio, commented: "We are pleased to partner with AffyXell Theapeutics and are honored to support this next-generation cell therapy project with ProBio’s stable and high-yield viral vector platform. We expect many patients to benefit from this innovative genetically modified mesenchymal stem cells therapy soon.”
As a result of the CDMO agreement, ProBio reaffirmed its commitment to AffyXell Therapeutic’s success and intends to participate in the next round of fundraising.
This collaboration with AffyXell Therapeutics represents another milestone in the realization of ProBio’s vision to proactively provide end-to-end expertise and support in developing novel therapeutics with transformational potential using new modalities such as gene editing. As strategic partners, both companies intend to collaborate in the areas of business development and licensing.
AffyXell Therapeutics Co., Ltd. is a joint venture between Daewoong Pharmaceutical and Avacta Group, developing a novel cell & gene therapy to obstacle diseases that come from the imbalance of immune system homeostasis. AffyXell’s platform (also known as AFX) is created by converging the two proprietary technologies of its parent companies – Daewoong’s mesenchymal stem cell (MSC) and Avacta’s Affimer® platform. The immunomodulation function by MSC is further increased with the Affimer®, and the treatment developed by the AFX platform enhances restoring immunologic balance. AffyXell is developing pipelines taking this new therapeutic approach to lead in resolving fundamental causes of intractable diseases like immune rejection and autoimmune diseases.
More information: http://affyxell.com/en/
ProBio is the subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine, biologics discovery and antibody protein drug to accelerate drug development for customers.
ProBio’s total cell and gene therapy solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing. ProBio’s innovative solutions for biologics discovery and development include therapeutic antibody discovery, antibody engineering and antibody characterization. GMP capacity which meets FDA, EMA and NMPA regulatory requirements.
Toward the mission of “Innovation through Collaboration”, ProBio is committed to helping customers shorten the timeline for the development of biological drugs from discovery to commercialization, significantly lowering R&D costs and building a healthier future.
More information: https://www.probiocdmo.com/